Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia

Leukemia, Published online: 10 April 2024; doi:10.1038/s41375-024-02241-7Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia

Source: Leukemia - April 10, 2024 Category: Hematology Authors: Hayden L. Bell Helen J. Blair Samantha J. Jepson Gosling Martin Galler Daniel Astley Anthony V. Moorman Olaf Heidenreich Gareth J. Veal Frederik W. van Delft John Lunec Julie A. E. Irving Source Type: research